

Reference List



Jameel A, Meiwald A, Bain P, et al. The Cost-Effectiveness of unilateral magnetic Resonance-Guided focused ultrasound in comparison to unilateral deep brain stimulation for the treatment of medically refractory essential tremor in England. *BJR*. 2022 Sep 20; 20220137. Available from: <https://doi.org/10.1259/bjr.20220137>

Vankelegom M, Burke D, Mohammed AMF, et al. Cost-effectiveness of a rapid point-of-care test for diagnosing patients with suspected bloodstream infection in Ireland. *Informatics in Medicine Unlocked*. 2022 Jan 1; 32:101056. Available from: <https://www.sciencedirect.com/science/article/pii/S2352914822001952>

Dombrowski CA, Weston GM, Descamps PP, et al. Health economic evaluation of an mRNA high-risk human papillomavirus (HR-HPV) assay versus a DNA HR-HPV assay for the proposed French cervical screening programme. *Medicine (Baltimore)*. 2022 Jul 22;101(29): e29530.

Meiwald A, Gara-Adams R, Rowlandson A, et al. Qualitative Validation of COPD Evidenced Care Pathways in Japan, Canada, England, and Germany: Common Barriers to Optimal COPD Care. *Int J Chron Obstruct Pulmon Dis*. 2022; 17:1507-1521 <https://doi.org/10.2147/COPD.S360983>

Huntington S, Weston G, Adams E. Assessing the clinical impact and resource use of a 30-minute chlamydia and gonorrhoea point-of-care test at three sexual health services. *Therapeutic Advances in Infectious Disease*. January 2021. doi:10.1177/204993612111061645

Gara-Adams R, Mowlem F, Thomas RH, et al. Care Pathway Mapping for Dravet Syndrome (DS) Patients in England – interim results from a pilot study. Presented at: ILAE British Branch Virtual Annual Scientific Conference, September 23 – 24, 2021; Virtual

Meiwald A, Gara-Adams R, Ma Y, et al. Analysing the COPD care pathway in Japan, Canada, England and Germany: a global view. Presented at: European Respiratory Society International Congress 2021, September 5 – 8, 2021; Virtual

Weston G, Dombrowski C, Steben M, et al. A health economic model to estimate the costs and benefits of an mRNA vs DNA high-risk HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada. *Preventive Medicine Reports* [Internet]. 2021 Sep 1; 23:101448. Available from: <https://www.sciencedirect.com/science/article/pii/S2211335521001388>

Pinsent A, Weston G, Adams EJ, et al. Determining the Relationship of Seizures, Seizure Free Days and Other Predictors of Health Related Quality of Life in Patients with Dravet Syndrome (DS) and Their Carers. Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 Congress, May 17 - 20, 2021; Virtual

- Weston G, Pinsent A, Adams EJ, *et al.* A Cost Effectiveness Analysis of Fenfluramine for the Treatment of Seizures for Patients with Dravet Syndrome (DS) in the UK Setting. Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 Congress, May 17 - 20, 2021; Virtual
- Dombrowski C, Weston G, Adams E. Modelling the impact of using a DNA compared to mRNA HPV assay as part of the cervical screening programmes in Sweden and Denmark. Poster presented at: EUROGIN International Multidisciplinary HPV Congress; 2021 May 30 - June 1; Virtual
- Dombrowski C, Weston G, Adams E. Evaluating the benefits and costs of using an mRNA versus DNA HR-HPV assay in the National Cervical Screening Programme in the Netherlands. Poster presented at: EUROGIN International Multidisciplinary HPV Congress; 2021 May 30 - June 1; Virtual
- Dombrowski C, Weston G, Descamps P, *et al.* Evaluating the choice of HPV assay in the French cervical screening programme with a decision tree model. Poster presented at: EUROGIN International Multidisciplinary HPV Congress; 2021 May 30 - June 1; Virtual
- Weston G, Steben M, Popadiuk C, Bentley J, *et al.* Estimating the costs and benefits of HR-HPV assay choice in a theoretical HPV primary cervical screening algorithm in Ontario, Canada. Poster presented at: EUROGIN International Multidisciplinary HPV Congress; 2021 May 30 - June 1; Virtual
- Kerry-Barnard S, Huntington, S, Fleming C, *et al.* Near patient chlamydia and gonorrhoea screening and treatment in further education/technical colleges: a cost analysis of the 'Test n Treat' feasibility trial. *BMC Health Services Research* (2020) 20:316 <https://doi.org/10.1186/s12913-020-5062-5>.
- Weston G, Dombrowski C, Harvey MJ, *et al.* Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation. *BMJ Open* 2020;10:e031303. doi:10.1136/bmjopen-2019-031303
- Micha A, Sinnett V, Wilson R, *et al.* P048. Interim analysis of an evaluation of clinical service impact of switching from wire to magnetic seeds for localisation of impalpable breast lesions for surgery. *Euro J Surg Oncology*, Vol 45, Issue 5, 898. DOI: <https://doi.org/10.1016/j.ejso.2019.01.070>
- Micha A, Sinnett V, Wilson R, *et al.* 30. Interim analysis of an evaluation of clinical outcome and patient and clinician satisfaction with magnetic seeds compared with guide wires for localisation of impalpable breast lesions for surgery. *Euro J Surg Oncology*, Volume 45, Issue 5, 884. DOI: <https://doi.org/10.1016/j.ejso.2019.01.216>
- Oakeshott P, Kerry-Barnard S, Fleming C, *et al.* "Test n Treat" (TnT): a cluster randomised feasibility trial of on-site rapid Chlamydia trachomatis tests and treatment in ethnically diverse, sexually active teenagers attending technical colleges. *Clin Microbiol & Inf.* Available 1 Nov 2018. doi.org/10.1016/j.cmi.2018.10.019.
- Aquarius Population Health, on behalf of the British In Vitro Diagnostics Association (BIVDA) and Innovate UK. Three simple tests could save the NHS at least £6.9 billion. London. June 2018. www.bivda.org.uk/3_simple_tests.pdf
- Kerry-Barnard S, Fleming C, Reid F, *et al.* 'Test n Treat (TnT)'- Rapid testing and same-day, on-site treatment to reduce rates of chlamydia in sexually active further education college students: study protocol for a cluster randomised feasibility trial. *Trials*. 2018 Jun 5;19(1):311. doi: 10.1186/s13063-018-2674-8.

Huntington SE, Burns RM, Harding-Esch E, et al. Modelling-based evaluation of the costs, benefits and cost-effectiveness of multi-pathogen point-of-care tests for sexually transmitted infections in symptomatic genitourinary medicine clinic attendees. *BMJ Open* 2018;8:e020394. doi: 10.1136/bmjopen-2017-020394

Vecino-Ortiz AI, Goldenberg SD, Douthwaite ST, et al. Impact of a multiplex PCR point-of-care test for influenza A/B and respiratory syncytial virus on an acute pediatric hospital ward. *Diag Micro & Infect Dis* 2018. doi.org/10.1016/j.diagmicrobio.2018.03.013

Harvey MJ, Cheng C-Y, Leone E, et al. Exploring HCV eradication through diagnosis and treatment strategies. EASL Monothematic Conference, Striving Towards the Elimination of HCV Infection. Berlin, Germany (2018).

Adams EJ, Cheng C-Y, Sacco J, et al. Mapping the treatment pathway for metastatic uveal melanoma patients in England: A qualitative pilot study. Society for Immunotherapy of Cancer's 32nd Annual Meeting, Maryland, USA (2017).

Cheng C-Y, Alamgir G, Adams EJ, et al. Quantifying standard of care (SOC) hospital-related resource utilisation for metastatic uveal melanoma (MUM) patients in NHS England (NHSE) using the hospital episodes statistics (HES) dataset. *Value in Health* **20**, A514 (2017).

Schwenkgenks M, Alamgir G, Cheng, C-Y, et al. A real-world evidence (RWE) approach to characterising an ultra-rare disease (URD) cohort of metastatic uveal melanoma (MUM) patients within National Health Service England (NHSE). *Value in Health* **20**, A730 (2017).

Whitlock GG, Gibbons, DC, Longford N, et al. Rapid testing and treatment for sexually transmitted infections improve patient care and yield public health benefits. *Int J STD & AIDS* 29(5):474-482 (Apr 2018). doi:10.1177/0956462417736431

Harding-Esch E, Huntington SE, Harvey MJ, et al. Cost-effectiveness of antimicrobial resistance point-of-care testing for optimising the treatment of gonorrhoea. *Sex Transm Infect* **93**, A34–A35 (2017).

Harding-Esch E, Huntington SE, Burns RM, et al. Evaluating the costs, benefits and cost-effectiveness of multi-pathogen point-of-care tests for sexually transmitted infections in symptomatic genitourinary medicine clinic attendees. *Sex Transm Infect* **93**, A205–A205 (2017).

Turner KM, Christensen H, Adams EJ, et al. Analysis of the potential for point-of-care test to enable individualised treatment of infections caused by antimicrobial-resistant and susceptible strains of *Neisseria Gonorrhoeae*: a modelling study. *BMJ Open* **7**, e015447 (2017).

Bustinduy AL, Jeyaratnam D, Douthwaite S, et al. Point-of-care tests for infectious diseases: barriers to implementation across three London teaching hospitals. *Acta Paediatrica* 106, 1192–1195 (2017).

Vecino Ortiz AI, Glover R & Adams EJ. Modelling the burden of bladder cancer and monitoring cystoscopies in Europe. *European Urology Suppl* **15**, e203 (2016).

Adams EJ. How to prevent cervical cancer: HPV – we are coming to get you! EUROGIN, Salzburg, Austria. (2016).

Vecino Ortiz AI, Glover RE, Douthwaite ST, et al. Estimating the clinical impact and costs of implementing a point of care test for influenza A/B and respiratory syncytial virus on an acute paediatric hospital inpatient ward. Society for Medical Decision Making, London, UK (2016).

Vecino Ortiz AI, Glover RE, Rabe AJ, *et al.* A rapid influenza test in hospitals could avoid unnecessary paediatric isolation bed days and save cost. Society for Medical Decision Making, London, UK (2016).

Douthwaite ST, Walker C, Adams EJ, *et al.* Performance of a novel point-of-care molecular assay for the detection of Influenza A, B and Respiratory Syncytial Virus (Enigma® MiniLab™) in children with acute respiratory infection. *J. Clin. Microbiol.* JCM.02887-15 (2015). doi:10.1128/JCM.02887-15

Adams EJ, Midha D, Postulka A, *et al.* Mapping the diagnostic pathway for breast cancer in England and comparison to Europe. *Value in Health* **18**, A477 (2015).

Adams EJ, Kendall E, Horner PJ, *et al.* Thinking critically about the value and cost of drugs: an example from managing patients with invasive fungal disease. 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2015), Copenhagen, Denmark (2015).

Alexander H, Munro-Wild H, Richards P, *et al.* Providing integrated HIV treatment and care for stable patients in general practice. 21st Annual Conference of the British HIV Association, Brighton, UK (2015).

Adams EJ, Glover R, Vecino Ortiz AI, *et al.* How can European countries improve cervical cancer prevention for women? 30th International Papillomavirus Conference, Lisbon, Portugal (2015).

Adams, EJ, Glover R, Vecino Ortiz AI, *et al.* Exploring the value of a rapid, on-demand test for the detection of human papillomavirus. 30th International Papillomavirus Conference, Lisbon, Portugal (2015).

Ceesay MM, Sadique Z, Harris R, *et al.* Prospective evaluation of the cost of diagnosis and treatment of invasive fungal disease in a cohort of adult haematology patients in the UK. *J Antimicrob Chemother* **70**, 1175–1181 (2015).

Taylor R, Carlin E, Sadique Z, *et al.* The financial and service implications of splitting fixed-dose antiretroviral drugs – a case study. *Int J STD AIDS* **26**, 75–80 (2015).

Horner P, Blee K & Adams EJ. Time to manage *Mycoplasma genitalium* as an STI: but not with azithromycin 1g! *Current Opinion in Infectious Diseases* **27**, 68 (2014).BTW

Price C, Adams EJ & Horner P. Point-of-care testing leads the way. *Parliamentary Review* (2014).

Adams EJ, Ehrlich A, Turner KM, *et al.* Mapping patient pathways and estimating resource use for point of care versus standard testing and treatment of chlamydia and gonorrhoea in genitourinary medicine clinics in the UK. *BMJ Open* **4**, e005322 (2014).

Hill C, Nasr R, Fisher MI, *et al.* Estimated cost and payment by results (PBR) tariff reimbursement for idiopathic pulmonary fibrosis services across 14 specialist providers in England. British Thoracic Society Winter Meeting, London, UK (2014).

Adams E, Ogden D, Ehrlich A, *et al.* Treatment for stable HIV patients in England: can we increase efficiency and improve patient care? *J Health Serv Res Policy* **19**, 131–137 (2014).

Turner KM, Round J, Horner P, *et al.* An early evaluation of clinical and economic costs and benefits of implementing point of care NAAT tests for Chlamydia trachomatis and Neisseria gonorrhoea in genitourinary medicine clinics in England. *Sex Transm Infect* **90**, 104–111 (2014).

Gillespie P, O'Neill C, Adams EJ, *et al.* The cost and cost-effectiveness of opportunistic screening for Chlamydia trachomatis in Ireland. *Sex Transm Infect* **88**, 222–228 (2012).

Turner KM, Adams EJ, Grant A, *et al.* Costs and cost effectiveness of different strategies for chlamydia screening and partner notification: an economic and mathematical modelling study. *BMJ* **342**, c7250 (2011).

Aghaizu A, Adams EJ, Turner KM, *et al.* What is the cost of pelvic inflammatory disease and how much could be prevented by screening for Chlamydia trachomatis? Cost analysis of the prevention of pelvic infection (POPI) trial. *Sex Transm Infect* **87**, 312–317 (2011).